Guangdong VTR Bio-Tech Co., Ltd. (SHE:300381)
China
· Delayed Price · Currency is CNY 6.93
-0.03 (-0.43%)
Apr 30, 2026, 11:05 AM CST
Guangdong VTR Bio-Tech Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | 2021 - 2017 |
| Operating Revenue | 832.26 | 821.47 | 790.19 | 1,149 | 1,838 | Upgrade
|
| Other Revenue | - | 4.73 | 5.83 | 24.81 | 53.95 | Upgrade
|
| Revenue | 832.26 | 826.2 | 796.02 | 1,174 | 1,892 | Upgrade
|
| Revenue Growth (YoY) | 0.73% | 3.79% | -32.20% | -37.95% | -1.18% | Upgrade
|
| Cost of Revenue | 454.22 | 460.33 | 459.12 | 816.91 | 1,217 | Upgrade
|
| Gross Profit | 378.04 | 365.87 | 336.9 | 357.1 | 675.22 | Upgrade
|
| Selling, General & Admin | 272.43 | 249.87 | 273.98 | 329.93 | 465.35 | Upgrade
|
| Research & Development | 104.95 | 109.32 | 99.82 | 99.87 | 129.78 | Upgrade
|
| Other Operating Expenses | 0.53 | 2.85 | 8.72 | 16.36 | 24.61 | Upgrade
|
| Operating Expenses | 377.91 | 363.48 | 365.74 | 445.99 | 654.69 | Upgrade
|
| Operating Income | 0.12 | 2.4 | -28.83 | -88.89 | 20.53 | Upgrade
|
| Interest Expense | - | -6.51 | -2.83 | -19.76 | -34.4 | Upgrade
|
| Interest & Investment Income | 1.76 | 15.5 | 27.89 | 175.88 | 1.78 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 2.66 | 0.65 | 15.31 | -9.01 | Upgrade
|
| Other Non Operating Income (Expenses) | -1.43 | -0.87 | -0.24 | -1.87 | -2.65 | Upgrade
|
| EBT Excluding Unusual Items | 0.45 | 13.18 | -3.35 | 80.67 | -23.76 | Upgrade
|
| Impairment of Goodwill | - | - | - | - | -80.83 | Upgrade
|
| Gain (Loss) on Sale of Investments | -4.98 | 9.36 | 5.38 | 8.89 | -2.28 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.1 | 3.01 | 0.05 | -0.06 | -0.23 | Upgrade
|
| Asset Writedown | -11.8 | -7.87 | -12.95 | -0.43 | -1.64 | Upgrade
|
| Other Unusual Items | - | 14.09 | 12.15 | 16 | 20.02 | Upgrade
|
| Pretax Income | -16.43 | 31.78 | 1.28 | 105.07 | -88.72 | Upgrade
|
| Income Tax Expense | 2.11 | -0.17 | 0.13 | 67.55 | -3.29 | Upgrade
|
| Earnings From Continuing Operations | -18.54 | 31.95 | 1.15 | 37.52 | -85.43 | Upgrade
|
| Minority Interest in Earnings | -1.24 | -0.86 | -11.9 | -19.29 | -33.48 | Upgrade
|
| Net Income | -19.78 | 31.09 | -10.75 | 18.23 | -118.91 | Upgrade
|
| Net Income to Common | -19.78 | 31.09 | -10.75 | 18.23 | -118.91 | Upgrade
|
| Shares Outstanding (Basic) | 491 | 490 | 491 | 490 | 490 | Upgrade
|
| Shares Outstanding (Diluted) | 491 | 490 | 491 | 490 | 490 | Upgrade
|
| Shares Change (YoY) | 0.08% | -0.09% | 0.15% | -0.01% | 4.75% | Upgrade
|
| EPS (Basic) | -0.04 | 0.06 | -0.02 | 0.04 | -0.24 | Upgrade
|
| EPS (Diluted) | -0.04 | 0.06 | -0.02 | 0.04 | -0.24 | Upgrade
|
| Free Cash Flow | -156.16 | -308.2 | -239.77 | 51.99 | 53.95 | Upgrade
|
| Free Cash Flow Per Share | -0.32 | -0.63 | -0.49 | 0.11 | 0.11 | Upgrade
|
| Dividend Per Share | - | 0.100 | 0.060 | 0.100 | 0.100 | Upgrade
|
| Dividend Growth | - | 66.67% | -40.00% | - | 42.86% | Upgrade
|
| Gross Margin | 45.42% | 44.28% | 42.32% | 30.42% | 35.69% | Upgrade
|
| Operating Margin | 0.01% | 0.29% | -3.62% | -7.57% | 1.08% | Upgrade
|
| Profit Margin | -2.38% | 3.76% | -1.35% | 1.55% | -6.28% | Upgrade
|
| Free Cash Flow Margin | -18.76% | -37.30% | -30.12% | 4.43% | 2.85% | Upgrade
|
| EBITDA | 129.06 | 114.28 | 82.84 | 48.96 | 188.39 | Upgrade
|
| EBITDA Margin | 15.51% | 13.83% | 10.41% | 4.17% | 9.96% | Upgrade
|
| D&A For EBITDA | 128.94 | 111.88 | 111.68 | 137.85 | 167.86 | Upgrade
|
| EBIT | 0.12 | 2.4 | -28.83 | -88.89 | 20.53 | Upgrade
|
| EBIT Margin | 0.01% | 0.29% | -3.62% | -7.57% | 1.08% | Upgrade
|
| Effective Tax Rate | - | - | 9.92% | 64.29% | - | Upgrade
|
| Revenue as Reported | - | 826.2 | 796.02 | 1,174 | 1,892 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.